Inactive Instrument

Highlights ERYTECH Pharma LIQUIDNET SYSTEMS

Equities

Phaxiam: fewer funds raised than expected	06-28	CF
Phaxiam: capital increase of ten million euros	06-12	CF
Phaxiam initiates trial in infective endocarditis	04-15	CF
PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	04-15	CI
PHAXIAM Therapeutics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
PHAXIAM Therapeutics Completes Delisting of ADS From Nasdaq	03-11	MT
Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing...	02-21
Phaxiam to delist ADS from Nasdaq in March	02-21	CF

No results for this search